Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia
References (27)
- et al.
Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme. A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity
FEBS Lett
(1976) - et al.
Rapid and substantial lowering of human serum cholesterol by mevinoJin (MK-803], an inhibitor of hydroxymethylglutaryl-coenzyme A reductase
Atherosclerosis
(1982) - et al.
Bile sequestrant therapy alters the compositions of low-density and high-density lipoproteins
Metabolism
(1979) - et al.
High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study
Am J Med
(1977) - et al.
Effects of combination cholestyramine-neomycin treatment on plasma lipoprotein concentrations in type II hyperlipoproteinemia
Am J Cardiol
(1985) - et al.
Serum cholesterol, lipoproteins, and risk of coronary heart disease: the Framingham Study
Ann Intern Med
(1971) - et al.
Probability of middle-aged men developing coronary heart disease in five years
Circulation
(1972) Relationship of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: final report of the pooling project
J Chron Dis
(1979)- et al.
Familial hypercholesterolemia
Lipid Research Clinics Coronary Primary Prevention Trial. Results. I. Reduction in incidence of coronary heart disease
JAMA
(1984)
Lipid Research Clinics Coronary Primary Prevention Trial. Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
JAMA
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia
N Engl J Med
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia
J Clin Invest
Cited by (78)
Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: A prospective, observational 56-month follow-up study
2016, Journal of Clinical LipidologyCitation Excerpt :Most statins are similar in structure to the enzyme's substrate, HMG-CoA, and act as competitive inhibitors. Inhibition of this enzyme by statins translates into lowering low-density lipoprotein (LDL) cholesterol via enhanced LDL receptor expression.3,4 As high LDL levels are causally associated with increased cardiovascular disease (CVD), statin treatment is effective in the primary and secondary prevention of CVD that is generally safe and well tolerated.5–8
Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease
2011, Cardiology ClinicsCitation Excerpt :Lovastatin, the first commercially developed statin, was approved for clinical use in 1987. Initial studies on both healthy volunteers15 and those with hypercholesterolemia16 showed a 28% to 45% reduction in LDL levels from baseline. Head-to-head trials were conducted in the late 1980s comparing statins with the other classes of lipid-lowering agents.
Simvastatin in primary biliary cirrhosis: Effects on serum lipids and distinct disease markers
2002, Journal of HepatologyAdenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: Receptor expression modulates high-density lipoproteins
1996, Metabolism: Clinical and ExperimentalCost-effectiveness analysis in heart disease, part II: Preventive therapies
1995, Progress in Cardiovascular Diseases